Sandbox: malabsorption: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 58: Line 58:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
*
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
Line 94: Line 95:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
*
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
Line 135: Line 137:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
*
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ↓
Line 165: Line 168:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
*
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
*
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
Line 200: Line 205:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
*
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 234: Line 240:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
*
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
Line 267: Line 274:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
*
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 272: Line 280:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
*
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
*
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
*
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 290: Line 301:
!
!
!
!
*
!
!
!
!
Line 295: Line 307:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 313: Line 328:
!
!
!
!
*
!
!
!
!
Line 318: Line 334:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 344: Line 363:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
*
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 377: Line 397:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
*
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
*
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
*
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |  
Line 446: Line 469:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
*
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ↓
Line 454: Line 478:
* [[Folate deficiency|Low folic acid]]
* [[Folate deficiency|Low folic acid]]
* [[Hypokalemia]] 
* [[Hypokalemia]] 
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
*
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |  
* Unknown
* Unknown
Line 478: Line 503:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
*
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
Line 508: Line 534:
!
!
!
!
*
!
!
!
!
Line 513: Line 540:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 550: Line 580:
* Elevated serum lactate  
* Elevated serum lactate  
!
!
*
!
!
* Recent antibiotics use
* Recent antibiotics use
Line 570: Line 601:
!
!
!
!
*
!
!
!
!
Line 575: Line 607:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 593: Line 628:
!
!
!
!
*
!
!
!
!
Line 598: Line 634:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 616: Line 655:
!
!
!
!
*
!
!
!
!
Line 621: Line 661:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 640: Line 683:
!
!
!
!
*
!
!
!
!
Line 645: Line 689:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 663: Line 710:
!
!
!
!
*
!
!
!
!
Line 668: Line 716:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 686: Line 737:
!
!
!
!
*
!
!
!
!
Line 691: Line 743:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 709: Line 764:
!
!
!
!
*
!
!
!
!
Line 714: Line 770:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 732: Line 791:
!
!
!
!
*
!
!
!
!
Line 737: Line 797:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 755: Line 818:
!
!
!
!
*
!
!
!
!
Line 760: Line 824:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 778: Line 845:
!
!
!
!
*
!
!
!
!
Line 783: Line 851:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 801: Line 872:
!
!
!
!
*
!
!
!
!
Line 806: Line 878:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 824: Line 899:
!
!
!
!
*
!
!
!
!
Line 829: Line 905:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 860: Line 939:
*Immune system analysis may show defects
*Immune system analysis may show defects
!
!
*
!
!
!
!
Line 903: Line 983:
!
!
!
!
*
!
!
!
!
Line 908: Line 989:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 926: Line 1,010:
!
!
!
!
*
!
!
!
!
Line 931: Line 1,016:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 949: Line 1,037:
!
!
!
!
*
!
!
!
!
Line 954: Line 1,043:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 972: Line 1,064:
!
!
!
!
*
!
!
!
!
Line 977: Line 1,070:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 1,008: Line 1,104:
*CD 4 level decreased as it is maily associated with HIV
*CD 4 level decreased as it is maily associated with HIV
!
!
*
!
!
!
!
Line 1,021: Line 1,118:
!
!
!
!
*
!
!
!
!
Line 1,026: Line 1,124:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 1,045: Line 1,146:
!
!
!
!
*
!
!
!
!
Line 1,050: Line 1,152:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 1,068: Line 1,173:
!
!
!
!
*
!
!
!
!
Line 1,073: Line 1,179:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 1,092: Line 1,201:
!
!
!
!
*
!
!
!
!
Line 1,097: Line 1,207:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 1,115: Line 1,228:
!
!
!
!
*
!
!
!
!
Line 1,120: Line 1,234:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 1,138: Line 1,255:
!
!
!
!
*
!
!
!
!
Line 1,143: Line 1,261:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 1,161: Line 1,282:
!
!
!
!
*
!
!
!
!
Line 1,166: Line 1,288:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 1,184: Line 1,309:
!-
!-
!
!
*
!+
!+
!+
!+
Line 1,189: Line 1,315:
!-
!-
!
!
*
!↑
!↑
!-
!-
!
!
!
!
*
!
!
*
!
!
!
!
Line 1,209: Line 1,338:
!+/-
!+/-
!
!
*
!+
!+
!+
!+
Line 1,214: Line 1,344:
!-
!-
!
!
*
!↑
!↑
!-
!-
!-
!-
!
!
*
!
!
*
!
!
!
!
Line 1,233: Line 1,366:
!
!
!
!
*
!
!
!
!
Line 1,238: Line 1,372:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 1,265: Line 1,402:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
*
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 1,301: Line 1,439:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
*
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
Line 1,325: Line 1,464:
!
!
!
!
*
!
!
!
!
Line 1,330: Line 1,470:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 1,348: Line 1,491:
!
!
!
!
*
!
!
!
!
Line 1,353: Line 1,497:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 1,384: Line 1,531:
*May be associated with FAP gene or HNPCC gene
*May be associated with FAP gene or HNPCC gene
!
!
*
!
!
!
!
Line 1,398: Line 1,546:
!
!
!
!
*
!
!
!
!
Line 1,403: Line 1,552:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 1,421: Line 1,573:
!
!
!
!
*
!
!
!
!
Line 1,426: Line 1,579:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 1,444: Line 1,600:
!
!
!
!
*
!
!
!
!
Line 1,449: Line 1,606:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 1,467: Line 1,627:
!
!
!
!
*
!
!
!
!
Line 1,472: Line 1,633:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 1,490: Line 1,654:
!
!
!
!
*
!
!
!
!
Line 1,495: Line 1,660:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 1,522: Line 1,690:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
*
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
Line 1,552: Line 1,721:
!
!
!
!
*
!
!
!
!
Line 1,557: Line 1,727:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 1,575: Line 1,748:
!
!
!
!
*
!
!
!
!
Line 1,580: Line 1,754:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 1,606: Line 1,783:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
*
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 1,641: Line 1,819:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
*
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 1,670: Line 1,849:
!
!
!
!
*
!
!
!
!
Line 1,675: Line 1,855:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
Line 1,693: Line 1,876:
!
!
!
!
*
!
!
!
!
Line 1,698: Line 1,882:
!
!
!
!
*
!
!
!
!
!
!
!
!
*
!
!
*
!
!
!
!
|- }
|- }
|}
|}

Revision as of 17:22, 12 December 2017

Diarrhea

Abbreviations: GI: Gastrointestinal, WBC: White blood cells, Plt: Platelets, Hgb: Hemoglobin, IgE: Immunoglobulin E, IgA: Immunoglobulin A, ETEC: Escherichia coli enteritis, EPEC: Enteropathogenic Escherichia coli, EIEC: Enteroinvasive Escherichia coli, EHEC: Enterohemorrhagic Escherichia coli, EAEC: Enteroaggregative Escherichia coli

Categories Cause Clinical manifestation Lab findings Extra intestinal findings Cause/Pathogenesis Gold standard diagnosis
Symptoms GI signs
Duration Diarrhea Fever Abdominal pain Weight loss
Stool exam CBC Other lab findings
Acute Chronic Watery Bloody Fatty WBC RBC Ova/Parasite Osmotic gap Other WBC Hgb Plt
Gastrointestinal Crohns disease - + + + + ± + + + + - -
  • Abnormal immune response to self antigens
Ulcerative colitis - + + + + + + + -
  • Hypoalbuminemia
  • Hypokalemia
  • Hypomagnesemia
  • Iron deficiency
  • Elevated ESR
  • Elevated CRP
  • Abnormal immune response to self antigens
Celiac disease - + ± - ± - + +
- -
  • IgA endomysial antibody
  • Anti-tissue transglutaminase antibody
  • Anti-gliadin antibody
  • IgA endomysial antibody
  • IgA tissue transglutaminase antibody
Cystic fibrosis - + - - + ± + +
- -
  • Positive DNA analysis for CFTR
  • Evaluated nasal transepithelial potential difference (NPD)
Chronic pancreatitis - + + - + - + +
- - -
  • Slightly elevated amylase and lipase
  • Abnormal pancreatic function test
  • Repeated acute pancreatitis
  • Alcohol abuse
  • Genetic
  • Autoimmune
Microscopic colitis - + + + - - + + -
- -
Infective colitis
Ischemic colitis
Mesenteric ischemia
Lactose intolerance + + + - - - + -
- - -
Irritable bowel syndrome - + ± - ± - ± - -
- - -
  • Diagnosis of exclusion
Infection Bacterial Whipple's disease - + + - + ± + + - - - ↓/↑
Tropical sprue + + + - + + + +
- -
  • Diagnosis of exclusion
Small bowel bacterial overgrowth - + + - + - + +
- -
  • Excess bacteria in the small intestine
  • Alterations in intestinal anatomy or GI motility, 
  • Lack of gastric acid secretion
  • Diagnosis of exclusion
Food poisoning
Pseudomembranous colitis + - + +/- - + + +/-
  • Abdominal tenderness
  • Presence of pseudomembranes of endoscopy
  • Enzyme immunoassay (EIA) for C difficile toxin A and B
  • Polymerase chain reaction (PCR) assay or C difficile antigen (glutamate dehydrogenase [GDH]) EIA
  • Leukocytosis
  • Elevated serum creatinine
  • Hypoalbuminemia
  • Anasarca
  • Elevated serum lactate
  • Recent antibiotics use
  • Recent surgery
  • Colon cancer
  • Diverticulitis
  • Appendicitis
  • Stool exam
  • CT
Shigella
Salmonella
Campylobacter jejuni
E-coli ETEC + -
EPEC
EIEC
EHEC
EAEC
Yersinia enterocolitica
Vibrio cholera
Aeromonas
Plesiomonas
Mycobacterium avium complex + + +/- + -
+/- + - -
- -
  • Immune system analysis may show defects
Other infections
  • aaaa
  • bbbb
+ + - + +/-
+ + - -
  • Stool culture may be positive for responsible organism
- -
Virus Rotavirus
Echovirus
Adenovirus
Norovirus
CMV colitis + + +/- + -
+/- + - -
- -
  • CD 4 level decreased as it is maily associated with HIV
HIV
Hepatitis Hepatitis A
Hepatitis E
Parasite Entamoeba histolytica
Giardia
Cryptosporidium
Microsporidia
Isospora + + + -
+ + - -
-
Other Parasitic diarrhea
  • aaaa
  • bbbb
+ + + - + +/-
+ + + -
- -
Tumors Carcinoid tumor
VIPoma + + + - + - + +
- - -
  • Primary secretory tumor
  • Elevated VIP levels
  • Followed by imaging
Zollinger-Ellison syndrome - + + - + - + +
- -
  • Elevated basal or stimulated serum gastrin> 120 pg/mL
Somatostatinoma
Lymphoma
Colorectal cancer + + + +
- + - -
- ↑/↓ -
  • May be associated with FAP gene or HNPCC gene
Medication/Toxicity Drug induced enteritis
Laxative abuse
Heavy metal ingestion
Organophosphate poisoning
Opium withdrawal
Iatrogenic Short bowel syndrome + + + - + - - +
-
  • Prior intestinal surgery
  • Surgical intestinal resection
Radiation enteritis
Dumping syndrome
Others Abetalipoproteinemia - + + - + - + +
- - -
Hyperthyroidism - + + - - ± + +
- - -
  • Elevated T4
  • Elevated T3
  • Decreased TSH
Diabetic neuropathy
Systemic sclerosis